NASDAQ
20.12.24
21:59 Uhr
7,450 US-Dollar
-0,350
-4,49 %
-4,49 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Sa | Insider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Sells 1,291 Shares of Stock | 4 | MarketBeat | ||
| 16.12. | Frank Karbe kauft Phathom Pharmaceuticals-Aktien im Wert von 99.083 US-Dollar | 3 | Investing.com Deutsch | ||
| 16.12. | Phathom Pharmaceuticals-Direktor Asit Parikh kauft Aktien im Wert von 81.248 US-Dollar | 9 | Investing.com Deutsch | ||
| 12.12. | Do You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)? | 7 | Insider Monkey | ||
| 07.11. | Phathom Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.11. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.10. | Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024 | 2 | GlobeNewswire (USA) | ||
| PHATHOM PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 27.10. | Phathom Pharmaceuticals to Present VOQUEZNA Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 07.10. | Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 7.5% - Should You Sell? | 3 | MarketBeat | ||
| 29.08. | Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences | 3 | GlobeNewswire (USA) | ||
| 19.08. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.08. | Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants | 5 | GlobeNewswire (USA) | ||
| 08.08. | Phathom Pharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 08.08. | Phathom Pharmaceuticals Non-GAAP EPS of -$1.25, revenue of $7.3M | 2 | Seeking Alpha | ||
| 08.08. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.08. | Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update | 214 | GlobeNewswire (Europe) | Over 122,000 prescriptions for VOQUEZNA® products written by healthcare providers, launch to date, a 184% increase since last quarterly reportNet revenues of $7.3 million reported for the second quarter... ► Artikel lesen | |
| 30.07. | Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients | 12 | GlobeNewswire (USA) | ||
| 18.07. | Heartburn Drug from Phathom Pharma Expands Its Approval to Cover More GERD Patients | 2 | MedCity News | ||
| 18.07. | Phathom Pharma announces Voquezna label expansion | 1 | Seeking Alpha | ||
| 18.07. | Phathom Pharma's Voquezna 10 Mg Gets FDA Approval For Non-erosive GERD | 1 | RTTNews |
Seite:
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,110 | -17,16 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,364 | -0,27 % | Defence Therapeutics Inc.: Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 9,900 | +2,06 % | Ginkgo Bioworks eligible for $9.4M in partnership for bioelectronic devices | ||
| RECURSION PHARMACEUTICALS | 6,035 | -0,90 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,000 | +8,01 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,730 | 0,00 % | Oncolytics Biotech (TSE:ONC) Stock Price Up 14.5% - Here's What Happened | ||
| ARCTURUS THERAPEUTICS | 15,500 | +4,45 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,891 | +5,72 % | Assertio Holdings, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 17,400 | -2,68 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| SIGA TECHNOLOGIES | 5,930 | -1,66 % | SIGA Technologies Inc.: Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced | Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study armsResults... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,340 | -0,27 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 16,400 | -0,61 % | Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,735 | +11,04 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,895 | -2,85 % | Where Will Summit Therapeutics Be in 5 Years? | ||
| ARVINAS | 18,480 | +3,65 % | Arvinas, Pfizer Report Positive Data From Phase 1b Study Of Vepdegestrant Combination Therapy | NEW YORK CITY (dpa-AFX) - Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE), Tuesday announced preliminary data from the ongoing Phase 1b portion of the TACTIVE-U sub-study of Vepdegestrant in combination... ► Artikel lesen |
PHATHOM PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -4,49 % bei einem Aktienkurs von 7,450 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHATHOM PHARMACEUTICALS INC finden Sie auf Wallstreet Online.
